CD4 and adenocarcinoma: Recently, a new mouse model of CAC genetically engineered mice to express the dominant negative TGFβ receptor II in CD4 and CD8 T cells (CD4-dnTGFβRII/AOM), and after challenge with a single dose of AOM, they formed macroscopically invisible flat adenocarcinoma lesions [10].